Tradestie Institutional Equity Comparison Engine

DCM vs HIT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HIT Overall Edge

HIT Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Health In Tech, Inc. Class A Common Stock (HIT) driven by superior Valuation, Growth & Margin while DCM counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DCM trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HIT at 8.8x Forward P/E and -45.8% operating margin (-22.4% YoY). In options structure, DCM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against HIT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner HIT
DCM N/M vs HIT 8.8x Fwd P/E
Growth & Margin Winner HIT
Op Margin N/A vs -45.8% ยท YoY N/A vs -22.4%
Momentum & Technical Winner DCM
1Y -34.4% vs -72.3% ยท 52W Pos 0% vs 5%
Options & Structure Winner DCM
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
DCM US Equity
DCM
Institutional Equity
$2.82
-6.62% 1D
Market Cap N/A
1M Return -26.75%
1Y Return -34.42%
Forward P/E N/M
Unified AI Score
48.8 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
HIT NASDAQ
Health In Tech, Inc. Class A Common Stock
Insurance Agents, Brokers & Service
$0.38
+12.36% 1D
Market Cap $27.1M
1M Return -33.48%
1Y Return -72.27%
Forward P/E 8.8x
Unified AI Score
39.6 / 100 SELL
Tech 48.0 Fund 45.0 Flow 50.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DCM -34.42% HIT -72.27% Spread: +5.32 pp (DCM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DCM TTM Op. Margin: N/A HIT TTM Op. Margin: -45.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCM vs HIT. Trailing 12-month operating profitability (DCM N/A vs HIT -45.8%) and valuation multiples (DCM N/M vs HIT 8.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DCM (2) vs HIT (8)
Institutional Metric DCM HIT Criterion Row Winner
Market Capitalization Scale N/A $27.1M Larger Scale HIT
Trailing P/E Ratio Valuation N/M 8.8x Lower Multiple HIT
Forward P/E Ratio Valuation N/M 8.8x Lower Multiple HIT
Revenue Growth (YoY) Growth N/A -22.4% Higher Growth HIT
Operating Margin (TTM) Profitability N/A -45.8% Higher Margin HIT
Net Profit Margin Profitability N/A -37.1% Higher Margin HIT
Return on Equity (ROE) Capital Efficiency N/A -76.6% Higher ROE HIT
52-Week Range Position Momentum 0% ($3โ€“$5) 5% ($0โ€“$2) Stronger Trend HIT
Beta / 30D Volatility Risk Regime N/A 0.95ฮฒ ยท 152% Vol Lower Realized Risk DCM
Unified Institutional Score Composite Signal 48.8 / 100 (HOLD) 39.6 / 100 (SELL) Higher Composite DCM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DCM vs HIT Buy Guide
DCM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DCM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HIT BREAKDOWN
174d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live HIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DCM nor HIT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.